

Electronic Acknowledgement Receipt

EFS ID:	5214195
Application Number:	09589288
International Application Number:	
Confirmation Number:	1519
Title of Invention:	METHODS OF INHIBITING B LYMPHOCYTES USING ANTIBODIES TO NEUTROKINE-ALPHA
First Named Inventor/Applicant Name:	Guo-Liang Yu
Customer Number:	73326
Filer:	John Jr. Kilyk/Himanshu Thakur
Filer Authorized By:	John Jr. Kilyk
Attorney Docket Number:	PF343P3C5
Receipt Date:	24-APR-2009
Filing Date:	08-JUN-2000
Time Stamp:	13:32:22
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment		no			
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Foreign Reference	EP1294769A2-1.pdf	22500420	no	350
			273c749910773108a7690816f63b42708e36db		
Warnings:					
Information:					

2	Foreign Reference	EP1294769A2-2.pdf	10796595 0f51c2e819160ab9761846e4c252515190184725	no	350
Warnings:					
Information:					
3	Foreign Reference	EP1294769A2-3.pdf	8304449 41c53c4ab6938336c2637be1463cb1f3d9316e	no	350
Warnings:					
Information:					
4	Foreign Reference	EP1294769A2-4.pdf	8437707 103ca22f18beeb3aaf57bcb98da1934e8232437f	no	350
Warnings:					
Information:					
5	Foreign Reference	EP1294769A2-5.pdf	8429805 3b4d5db1bf57acbf6a7abaf108b53b166870f	no	350
Warnings:					
Information:					
6	Foreign Reference	EP1294769A2-6.pdf	8416016 72a08ce08ae4463e9d9ee6dc0d4276be652aaf	no	350
Warnings:					
Information:					
7	Foreign Reference	EP1294769A2-7.pdf	8399822 68f4426bab167effcd9a1e1eaf67c18187d8abb	no	350
Warnings:					
Information:					
8	Foreign Reference	EP1294769A2-8.pdf	8336710 52ba0169dbf7242b6ca84ab1ee346e45e7445d	no	350
Warnings:					
Information:					
9	Foreign Reference	EP1294769A2-9.pdf	7026114 4dfc50a98f178ca1902b5c4671aa116af6b708ff	no	348
Warnings:					
Information:					
10	Foreign Reference	EP1456347A2-1.pdf	22309473 6c0f4a04d3e7d52dd9eaf050c2722483a429e5	no	350
Warnings:					
Information:					

11	Foreign Reference	EP1456347A2-2.pdf	10741054 57a7bc106a76a066905a2e198a41a508007aaf600	no	350
Warnings:					
Information:					
12	Foreign Reference	EP1456347A2-3.pdf	8676887 877cc6a1810a99b7774803e13932a58e3cc0bae088	no	350
Warnings:					
Information:					
13	Foreign Reference	EP1456347A2-4.pdf	8691683 d8d6b472594c13178b44181b6d442638450aacf7	no	350
Warnings:					
Information:					
14	Foreign Reference	EP1456347A2-5.pdf	8872298 5459578b7d22182a2d44d8604f799db3485572785	no	350
Warnings:					
Information:					
15	Foreign Reference	EP1456347A2-6.pdf	8872785 77eeaf1c95a056948814d85d1c505c1e72102d8d2	no	350
Warnings:					
Information:					
16	Foreign Reference	EP1456347A2-7.pdf	8896942 24211303d19c965c4033a8b8b83d6da28f8b276	no	350
Warnings:					
Information:					
17	Foreign Reference	EP1456347A2-8.pdf	15401974 66aff6c8a441a6a998bc3994aa7c225d773c9705	no	649
Warnings:					
Information:					
18	Foreign Reference	EP1507793A1-1.pdf	15702023 b092a043dc7a297c55ae7893b9487d862d24d6d8	no	250
Warnings:					
Information:					
19	Foreign Reference	EP1507793A1-2.pdf	14634644 d2451e6ab4078a08f1f65c52c4d39e93087695ca	no	270
Warnings:					
Information:					

20	Foreign Reference	EP1577391A1.pdf	799617 8bd4130f4a16d5180893b3a79e2d8b663944b4c	no	55
Warnings:					
Information:					
21	Foreign Reference	EP1860190A2.pdf	3421776 07dcd2573b13c541493a0d411af7555d44e45	no	247
Warnings:					
Information:					
22	NPL Documents	BiogenObservations-EP_1146892-2007.pdf	1878196 8a3161abb5a772e9654b5d6c8a7251004b3e91	no	38
Warnings:					
Information:					
23	NPL Documents	MelchersDeclaration-INT_105485-2006.pdf	1005734 3dc2e9b032173e9456a7a564a4b9cc029b5c	no	22
Warnings:					
Information:					
24	NPL Documents	SchlisselDeclaration-INT_105485-2006.pdf	22033339 9a7998843cd802e21215a49691a089317f8ec28	no	339
Warnings:					
Information:					
25	NPL Documents	SchlisselSecondDeclaration-INT_105485-2007.pdf	217497 aa5a63e6523a9ac451a6dc9e4f1754578c84dab4	no	7
Warnings:					
Information:					
26	NPL Documents	SchlisselThirdDeclaration-INT_105485-2007.pdf	1022280 12a1495c8b8c785a8dfe13bd92255d4cfac11	no	23
Warnings:					
Information:					
27	NPL Documents	NoelleDeclaration-INT_105485-2007.pdf	1968192 371a6b4f53e68508baf6382c775a6c38dfe6857	no	48
Warnings:					
Information:					
28	NPL Documents	SmithDeclaration-2004.pdf	6750607 801a2918b1a03ff03b2a2c45ca30a2d280cb7a	no	87
Warnings:					
Information:					

29	NPL Documents	SmithSecondDeclaration-2005.pdf	6321785 a1cd42c87a936fa738823774a6b8b6c4c9f e873	no	77
Warnings:					
Information:					
30	NPL Documents	MelchersDeclaration-EP_1146892-2007.pdf	1113442 db099eb4029c5584ed96c28c30030c5527b1a 862d0	no	25
Warnings:					
Information:					
31	NPL Documents	WareDeclaration-INT_105485-2007.pdf	919652 dec45f00b40fc3a77290190729011e08b55 d24	no	22
Warnings:					
Information:					
32	NPL Documents	GehaDeclaration-INT_105485-2007.pdf	1126934 7eac1c12f6f74ee2bb2b261dad38fed712d93 997b6	no	26
Warnings:					
Information:					
33	NPL Documents	DeclarationofInterference-INT_105485.pdf	335402 6161f240489429b4d7703ad781a0ba851eae5 5dfe	no	8
Warnings:					
Information:					
34	NPL Documents	GenbankAccessionNo-P01374.pdf	69182 65794c6d29cd3ddbf5db62baa511b290b57e ba86e6	no	8
Warnings:					
Information:					
35	NPL Documents	GenbankAccessionNo-CAA25649.pdf	53420 9813867324d8d0daaf95199036a7182415d 286c7	no	2
Warnings:					
Information:					
36	NPL Documents	HGSBackgrounder-BLymphocyteStimulator-2000.pdf	31082 83c4c4a20b67ac0d8a7074027bc2a88cf1b 8018	no	1
Warnings:					
Information:					
37	NPL Documents	HGSBackgrounder-SystemicLupusErythematosus-2000.pdf	97293 3d6a7941288b765cf5ad3f1ca23ace38a39 24cf	no	2
Warnings:					
Information:					

38	NPL Documents	HGSBackgrounder-ImmunoglobulinADeficiency-2001.pdf	176584 117b5d884c812d95c3b6542e4401ab779be92a73	no	3
Warnings:					
Information:					
39	NPL Documents	HGSPressRelease-HGSDiscoveryNovelImmuneStimulant-1999.pdf	215221 318ba92144f8ba4f9027a8b1a1288b364a12618d	no	3
Warnings:					
Information:					
40	NPL Documents	HGSPressRelease-HGSAdvanceHodgkinsLymphoma-1999.pdf	186393 a1b0980c78a8c5d45c8a6e9b6a088d2c5542b	no	3
Warnings:					
Information:					
41	NPL Documents	HGSPressRelease-NewAntiAngiogenicProteins-1999.pdf	193626 8a07b177150f0043e0e266e20115c203810395d6	no	3
Warnings:					
Information:					
42	NPL Documents	HGSPressRelease-HGSReports1999FinancialResults-2000.pdf	335734 6a055078546a69713d79093a538164965215	no	6
Warnings:					
Information:					
43	NPL Documents	HGSPressRelease-HGSReports1stQYFinancialResults-2000.pdf	273258 08a05caab95288d6c647ae94b52a19c08a1d49	no	6
Warnings:					
Information:					
44	NPL Documents	HGSPressRelease-HGSandCATAntiBlyisAntibodies-2000.pdf	192488 6243302d1155a7168ba74a019c935a86c0da79825	no	3
Warnings:					
Information:					
45	NPL Documents	HGSPressRelease-HighLevelsBlyisLupusRheumatoidArthritis-2000.pdf	169663 7e1007e0bdc527e7b55886a2278360013b1133c17	no	3
Warnings:					
Information:					
46	NPL Documents	HGSPressRelease-HGSandDOWRadioBlys-2000.pdf	162481 7aa210c36de5fa21418d05ec23c08f5308de72	no	2
Warnings:					
Information:					

47	NPL Documents	HGSPressRelease-HGSReportsFinancialResults4th QY-2001.pdf	448290 798bed016c728c8bc79798b674d65744be12a7f	no	7
Warnings:					
Information:					
48	NPL Documents	HGSPressRelease-HGSAntibodyMfgFacility-2001.pdf	143577 5abed7558834d9135f8ba35855bb8f6e32cb473bbac	no	2
Warnings:					
Information:					
49	NPL Documents	HGSPressRelease-HGSOrphanDrugDesignation-2001.pdf	154201 6cd4b686e1cafb6bca294dc69482762af6c4889	no	2
Warnings:					
Information:					
50	NPL Documents	HGSPressRelease-HGSLargeScaleMfgPlant-2001.pdf	125933 06c9a130ef503294f8023bf3c8b7db54226b191	no	2
Warnings:					
Information:					
51	NPL Documents	HGSPressRelease-HGSTrialSystemicLupusErythematosus-2001.pdf	1010845 9f98bc93048beba35a908f966d275a31c035c3f	no	18
Warnings:					
Information:					
52	NPL Documents	HGSPressRelease-HGSDataSupportPotentialLymphostatB-2001.pdf	17618 a4fa158bed8bb52823eb33559c9a362a06a8486c	no	2
Warnings:					
Information:					
53	NPL Documents	HGSPressRelease-HGSDataAmericanSocietyHematologyMeeting-2001.pdf	185567 4a0a6ccfca2187352c6a6842593b42408f3fa2	no	3
Warnings:					
Information:					
54	NPL Documents	HGSPressRelease-HGSInvestigationalDrugLymphorad131-2002.pdf	174073 040ba09f6b0dbae79f5a8cf588fb6de6a85eeaf1	no	2
Warnings:					
Information:					
55	NPL Documents	HGSPressRelease-HGSReports2001FinancialResults-2002.pdf	451937 29f1030532f6e023a702a8802a7246f6e042536	no	7
Warnings:					
Information:					

56	NPL Documents	HGSPressRelease-HGSProvidesUpdateCompanyProgress-2002.pdf	650887 #226848db7d0672584e8bb14737804829e6c0d1	no	8
Warnings:					
Information:					
57	NPL Documents	HGSPressRelease-HGSAnnouncesClearanceDrugApplicationLymphorad131-2002.pdf	218612 517e24b1c14225e930310a7f2a266798b1b13594	no	3
Warnings:					
Information:					
58	NPL Documents	HGSPressRelease-HGSActivityCancerDrugAmericanSocietyClinicalOncology-2002.pdf	190748 a71enc32c3c3200401312d6d8e9efad34db7c6b	no	3
Warnings:					
Information:					
59	NPL Documents	HGSPressRelease-HGSandCATDevelopmentAntibodyTrialReceptor2-2002.pdf	181975 6d006492175d5161e107c363eb2d48a2338b7d2	no	3
Warnings:					
Information:					
60	NPL Documents	HGSPressRelease-HGS2ndQY2002FinancialResults-2002.pdf	144471 c1093a75d3a94e0612a7b1d1d3083b1e6d6096da	no	3
Warnings:					
Information:					
Total Files Size (in bytes):			268617013		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.